Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane |
Domain |
PF00071 Ras family |
Function |
May play an important role in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca(2+) currents. Regulates voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane (By similarity). Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway. Inhibits phosphorylation and activation of CAMK2D. |
Biological Process | - |
Molecular Function |
GO:0003924 GTPase activity GO:0005516 calmodulin binding GO:0005525 GTP binding GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between RRAD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between RRAD and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of RRAD in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of RRAD in various data sets.
|
Points in the above scatter plot represent the mutation difference of RRAD in various data sets.
|
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RRAD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RRAD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RRAD. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RRAD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of RRAD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between RRAD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | RRAD |
Name | Ras-related associated with diabetes |
Aliases | REM3; RAD; RAS (RAD and GEM) like GTP binding 3; ras associated with diabetes; GTP-binding protein RAD |
Chromosomal Location | 16q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting RRAD collected from DrugBank database. |
There is no record. |